Navigation Links
Tengion Reports Fourth Quarter and Full Year 2011 Financial Results
Date:3/26/2012

to develop and commercialize its product candidates, including the Neo-Kidney Augment and the Neo-Urinary Conduit; and (ii) expectations regarding ongoing and planned preclinical studies and clinical trials.  Although Tengion believes that these statements are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there are a number of factors that may cause actual results to differ from these statements. For instance there can be no assurance that: (i) the Company will be able to successfully enroll patients in its clinical trials, including its Phase I clinical trial for the Neo-Urinary Conduit; (ii) patients enrolled in the Company's clinical trials will not experience adverse events related to the Company's product candidates, which could delay clinical trials or cause the Company to terminate the development of a product candidate; (iii) the results of the clinical trial for the Neo-Urinary Conduit will support further development of that product candidate; (iv) data from the Company's ongoing preclinical studies will continue to be supportive of advancing its preclinical product candidates; and (v) the Company will be able to progress its product candidates that are undergoing preclinical testing, including the Neo-Kidney Augment, into clinical trials; (vi) the Company will be able enter into strategic partnerships on favorable terms, if at all, or obtain the capital it needs to develop its product candidates and continue its operations and (vii) the Company will be able to reduce the net rental obligation for its Pennsylvania facility prior to the expiration of the existing lease.  For additional factors which could cause actual results to differ from expectations, reference is made to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.  The forward looking statements in this release are made only as of the date hereof
'/>"/>
SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... Oct. 29, 2014   ViaDerma, Inc. ... bringing new products to market, is committed to ... has developed an innovative, patent-pending dual carrier transdermal ... of pharmaceutical active ingredients to penetrate the skin ... therapy. The transdermal delivery method also overcomes microbial ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... 1b study planned for mid 2008 with Phase 2 development ... to begin late in 2008 or in early ... NUVO ) today announced positive results from the Phase 1,proof-of-concept ... offset of anticoagulation after,a single bolus dose with a favorable safety ...
... Erythematosus ... ... (Nasdaq: RIGL ) announced today that its lead product,candidate, R788, ... reported in a recently published,study of the drug candidate. R788 (fostamatinib ...
Cached Medicine Technology:Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 2Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 3Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 4Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 2Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 3Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 4
(Date:10/30/2014)... Chicago, IL (PRWEB) October 30, 2014 Dr. ... launched a new website for his practices; OB GYN ... Chicago, IL . This website contains important information about ... covers as well as downloadable patient forms in English and ... use and the service pages on the website provide Dr. ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
(Date:10/29/2014)... women at first acted surprised. Some insisted the blood tests ... not used the study products assigned to them as participants ... likely consequence, did not find any of the three products ... were among 127 former VOICE participants who, as part of ... in in-depth interviews and/or focus group discussions after learning the ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
... of hormone worsened respiratory disease , , THURSDAY, Nov. 20 ... may explain why women with cystic fibrosis tend to ... at the University of North Carolina report. , , ... 20 issue of the Journal of Clinical Investigation ...
... Reno,s Downtown Ballroom was transformed into a Cirque style extravaganza ... ballroom to help raise funds for one of Reno,s most ... residents and many of Nevada,s prominent leaders, including Nevada Governor ... To view the Multimedia News Release, go to: ...
... Nov. 20 Precyse Solutions, the leader in,driving ... management solutions, was recognized by the Eastern Technology,Council ... at the 16th,Enterprise Award Gala held at the ... top technology and life sciences companies and entrepreneurs. ...
... at risk for hospital visits of their own , , THURSDAY, ... for a loved one with Alzheimer,s results in 25 percent ... hospital visit every six months, says an Indiana University study. ... an Alzheimer,s patient is difficult, but the Indiana University researchers ...
... Quality Care , ARLINGTON HEIGHTS, Ill., Nov. 20 ... cannot afford to cut corners on quality of care, warns ... thing to temporarily substitute fillers for facelifts, ASPS says the ... professional training. This concern was discussed recently at the ASPS ...
... People are often reluctant to undergo a routine but ... be fatal. According to the American Cancer Society, colon ... American men and women and kills about 50,000 Americans ... cancer have no symptoms or family history," says Prof. ...
Cached Medicine News:Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:Photos: Nevada's Saint Mary's Regional Medical Center Raises $1.3 Million During Centennial Soiree 2Health News:Precyse Solutions Honored as 'Technology Company of the Year' 2Health News:When the Caregiver Becomes the Patient 2Health News:Caution Urged as Patients Seek Deals on Cosmetic Surgery 2Health News:A simple blood test for colon cancer 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: